Head of Research & Development Berman and Head of Infectious Diseases Dorrell discuss the recent progress in Immunocore’s HIV ImmTAV within its infectious disease program on a conference call to be held on February 22 at 3 pm hosted by H.C. Wainwright. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IMCR:
- Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
- Immunocore announces initial Phase 1 data for IMC-M113V
- Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
- Immunocore to participate in a conference call with H.C. Wainwright
- Immunocore management to meet with Oppenheimer